GUFICBIO Stock Overview
Manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Gufic Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹346.35 |
| 52 Week High | ₹386.95 |
| 52 Week Low | ₹211.00 |
| Beta | 0.82 |
| 11 Month Change | 7.88% |
| 3 Month Change | 22.60% |
| 1 Year Change | 48.23% |
| 33 Year Change | 90.09% |
| 5 Year Change | 371.55% |
| Change since IPO | 1,070.10% |
Recent News & Updates
Recent updates
We Think You Should Be Aware Of Some Concerning Factors In Gufic Biosciences' (NSE:GUFICBIO) Earnings
Jun 06
Is Gufic Biosciences (NSE:GUFICBIO) Using Too Much Debt?
Jun 17These 4 Measures Indicate That Gufic Biosciences (NSE:GUFICBIO) Is Using Debt Reasonably Well
Sep 02Should You Be Adding Gufic Biosciences (NSE:GUFICBIO) To Your Watchlist Today?
May 07Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock
Dec 07This Is The Reason Why We Think Gufic Biosciences Limited's (NSE:GUFICBIO) CEO Might Be Underpaid
Sep 15Is Now The Time To Put Gufic Biosciences (NSE:GUFICBIO) On Your Watchlist?
Aug 12Gufic Biosciences' (NSE:GUFICBIO) Performance Is Even Better Than Its Earnings Suggest
Jun 11If You Like EPS Growth Then Check Out Gufic Biosciences (NSE:GUFICBIO) Before It's Too Late
Mar 19What Percentage Of Gufic Biosciences Limited (NSE:GUFICBIO) Shares Do Insiders Own?
Mar 01Gufic Biosciences (NSE:GUFICBIO) Has A Pretty Healthy Balance Sheet
Feb 11Is Gufic Biosciences' (NSE:GUFICBIO) 164% Share Price Increase Well Justified?
Jan 23
Why Gufic Biosciences Limited (NSE:GUFICBIO) Looks Like A Quality Company
Jan 05Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock
Dec 18Here's What Gufic Biosciences Limited's (NSE:GUFICBIO) Shareholder Ownership Structure Looks Like
Dec 01Gufic Biosciences (NSE:GUFICBIO) Has A Somewhat Strained Balance Sheet
Nov 13The Gufic Biosciences (NSE:GUFICBIO) Share Price Has Gained 116%, So Why Not Pay It Some Attention?
Oct 19Can Gufic Biosciences Limited's (NSE:GUFICBIO) ROE Continue To Surpass The Industry Average?
Sep 14I Built A List Of Growing Companies And Gufic Biosciences (NSE:GUFICBIO) Made The Cut
Aug 24Investors Appear Satisfied With Gufic Biosciences Limited's (NSE:GUFICBIO) Prospects
Aug 03Earnings Tell The Story For Gufic Biosciences Limited (NSE:GUFICBIO)
Jul 09Shareholder Returns
| GUFICBIO | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.8% | -0.1% | 0.6% |
| 1Y | 48.2% | 46.8% | 45.2% |
Return vs Industry: GUFICBIO exceeded the Indian Pharmaceuticals industry which returned 46.8% over the past year.
Return vs Market: GUFICBIO exceeded the Indian Market which returned 45.2% over the past year.
Price Volatility
| GUFICBIO volatility | |
|---|---|
| GUFICBIO Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: GUFICBIO has not had significant price volatility in the past 3 months.
Volatility Over Time: GUFICBIO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | 1,628 | Pranav Choksi | www.gufic.com |
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. The company manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. It manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments.
Gufic Biosciences Limited Fundamentals Summary
| GUFICBIO fundamental statistics | |
|---|---|
| Market cap | ₹34.72b |
| Earnings (TTM) | ₹861.36m |
| Revenue (TTM) | ₹8.07b |
40.3x
P/E Ratio4.3x
P/S RatioIs GUFICBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUFICBIO income statement (TTM) | |
|---|---|
| Revenue | ₹8.07b |
| Cost of Revenue | ₹3.90b |
| Gross Profit | ₹4.17b |
| Other Expenses | ₹3.31b |
| Earnings | ₹861.36m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.59 |
| Gross Margin | 51.67% |
| Net Profit Margin | 10.68% |
| Debt/Equity Ratio | 59.5% |
How did GUFICBIO perform over the long term?
See historical performance and comparison